EGFR and non-small cell lung carcinoma: Although no molecular-targeted therapy has shown any overall survival benefit in early-stage NSCLC with EGFR mutations [10], advanced-stage NSCLC harboring sensitizing EGFR-positive mutations responds well to tyrosine kinase inhibitors (TKIs) and these agents have proven more effective than the historical standard of care, platinum-based chemotherapy [8].